JP2000511407A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2000511407A5 JP2000511407A5 JP1997538216A JP53821697A JP2000511407A5 JP 2000511407 A5 JP2000511407 A5 JP 2000511407A5 JP 1997538216 A JP1997538216 A JP 1997538216A JP 53821697 A JP53821697 A JP 53821697A JP 2000511407 A5 JP2000511407 A5 JP 2000511407A5
- Authority
- JP
- Japan
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US1611796P | 1996-04-24 | 1996-04-24 | |
| US60/016,117 | 1996-04-24 | ||
| US1778596P | 1996-05-15 | 1996-05-15 | |
| US60/017,785 | 1996-05-15 | ||
| PCT/US1997/006563 WO1997040145A1 (en) | 1996-04-24 | 1997-04-24 | Inactivation resistant factor viii |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2007101700A Division JP4250661B2 (ja) | 1996-04-24 | 2007-04-09 | 不活性化耐性第ｖｉｉｉ因子 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2000511407A JP2000511407A (ja) | 2000-09-05 |
| JP2000511407A5 true JP2000511407A5 (enExample) | 2004-12-02 |
| JP3987114B2 JP3987114B2 (ja) | 2007-10-03 |
Family
ID=26688196
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP53821697A Expired - Fee Related JP3987114B2 (ja) | 1996-04-24 | 1997-04-24 | 不活性化耐性第▲８▼因子 |
| JP2007101700A Expired - Fee Related JP4250661B2 (ja) | 1996-04-24 | 2007-04-09 | 不活性化耐性第ｖｉｉｉ因子 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2007101700A Expired - Fee Related JP4250661B2 (ja) | 1996-04-24 | 2007-04-09 | 不活性化耐性第ｖｉｉｉ因子 |
Country Status (10)
| Country | Link |
|---|---|
| US (2) | US6838437B2 (enExample) |
| EP (3) | EP0910628B1 (enExample) |
| JP (2) | JP3987114B2 (enExample) |
| AT (2) | ATE319817T1 (enExample) |
| AU (1) | AU3202797A (enExample) |
| CA (1) | CA2252896C (enExample) |
| DE (2) | DE69735421T2 (enExample) |
| DK (1) | DK1754718T3 (enExample) |
| PT (1) | PT1754718E (enExample) |
| WO (1) | WO1997040145A1 (enExample) |
Families Citing this family (41)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK0833848T3 (da) * | 1995-06-12 | 2001-11-05 | Sanquin Bloedvoorziening | Faktor IX-bindende peptider afledt af faktor VIII og anvendelse heraf som inhibitorer af blodkoagulation |
| US8183344B2 (en) | 1996-04-24 | 2012-05-22 | University Of Michigan | Inactivation resistant factor VIII |
| US20040092442A1 (en) * | 1996-04-24 | 2004-05-13 | University Of Michigan | Inactivation resistant factor VIII |
| EP0910628B1 (en) | 1996-04-24 | 2006-03-08 | The Regents of The University of Michigan | Inactivation resistant factor viii |
| AU3289599A (en) * | 1998-02-13 | 1999-08-30 | Cadus Pharmaceutical Corporation | Mekk1 proteins and fragments thereof for use in regulating apoptosis |
| EP1351986A2 (en) * | 2001-01-12 | 2003-10-15 | The American National Red Cross | Methods and compositions for reducing heparan sulfate proteoglycan-mediated clearance of factor viii |
| WO2003100053A1 (en) * | 2002-05-22 | 2003-12-04 | The Children's Hospital Of Philadelphia | Compositions and methods for the treatment of hemophilia a |
| US7041635B2 (en) | 2003-01-28 | 2006-05-09 | In2Gen Co., Ltd. | Factor VIII polypeptide |
| EP1502921A1 (en) * | 2003-07-29 | 2005-02-02 | ZLB Behring GmbH | Recombinant mutated human factor VIII (FVIII) with improved stability |
| CN101098883B (zh) * | 2004-12-23 | 2013-01-23 | 诺和诺德医疗保健公司 | 减少含有目的维生素k依赖性蛋白质的组合物中的蛋白质污染物的含量 |
| US20110124565A1 (en) * | 2005-04-14 | 2011-05-26 | Hans-Peter Hauser | Modified Coagulation Factor VIII With Enhanced Stability and Its Derivatives |
| EP1816201A1 (en) | 2006-02-06 | 2007-08-08 | CSL Behring GmbH | Modified coagulation factor VIIa with extended half-life |
| US20090203077A1 (en) * | 2006-06-30 | 2009-08-13 | The Regents Of The University Of Michigan | Method of producing factor viii proteins by recombinant methods |
| US20080070251A1 (en) * | 2006-06-30 | 2008-03-20 | Kaufman Randal J | Method of Producing Factor VIII Proteins by Recombinant Methods |
| US8754194B2 (en) | 2006-12-22 | 2014-06-17 | Csl Behring Gmbh | Modified coagulation factors with prolonged in vivo half-life |
| DK2865760T3 (en) | 2008-06-24 | 2018-01-15 | Csl Behring Gmbh | Factor VIII, Von Willebrand Factor or complexes thereof with extended in vivo half-life |
| CA2816575C (en) * | 2010-11-05 | 2019-06-11 | Baxter Healthcare S.A. | A new variant of antihemophilic factor viii having increased specific activity |
| SI23610A (sl) | 2011-01-13 | 2012-07-31 | Diagen@d@o@o | Nove adicijske soli ziprasidona postopek za njihovo pripravo in njihova uporaba v terapiji |
| KR20140083036A (ko) | 2011-10-18 | 2014-07-03 | 체에스엘 베링 게엠베하 | 인자 ｖｉｉｉ의 생체이용률을 향상시키기 위한 황산화 글리코사미노글리칸의 용도 |
| KR20140083035A (ko) | 2011-10-18 | 2014-07-03 | 체에스엘 베링 게엠베하 | 인자 ｖｉｉｉ의 생체이용률을 증가시키기 위한 황산화 글리코사미노글리칸과 하이알루로니다제의 병용 사용 |
| AU2012318292B2 (en) | 2011-10-18 | 2015-08-20 | Csl Limited | Method for improving the stability of purified Factor VIII after reconstitution |
| PL2814502T3 (pl) | 2012-02-15 | 2018-02-28 | Csl Behring Gmbh | Warianty czynnika von Willebranda mające ulepszone powinowactwo do wiązania czynnika VIII |
| US20150337028A1 (en) * | 2012-09-12 | 2015-11-26 | Centre For Bioseparation Technology-Vit | Double Mutant Coagulation Factor VIII and Methods Thereof |
| KR20150088853A (ko) | 2012-11-29 | 2015-08-03 | 바이엘 헬스케어 엘엘씨 | 활성화 단백질 c에 대한 인간화 모노클로날 항체 및 그의 용도 |
| EP2925351A4 (en) * | 2012-11-29 | 2016-08-24 | Bayer Healthcare Llc | MONOCLONAL ANTIBODIES DIRECTED AGAINST ACTIVATED PROTEIN C (APC) |
| US9914764B2 (en) | 2013-03-15 | 2018-03-13 | Bayer Healthcare, Llc | Variant factor VIII polypeptides and methods of their production and use |
| ES2657291T3 (es) | 2013-04-22 | 2018-03-02 | Csl Ltd. | Un complejo covalente de factor de von Willebrand y factor VIII asociado por un puente disulfuro |
| EP3114138B1 (en) | 2014-03-05 | 2021-11-17 | Pfizer Inc. | Improved muteins of clotting factor viii |
| EP3164150B1 (en) | 2014-07-02 | 2020-11-04 | CSL Behring Lengnau AG | Modified von willebrand factor |
| KR20170125941A (ko) | 2015-03-06 | 2017-11-15 | 체에스엘 베링 리컴비넌트 퍼실리티 아게 | 개선된 반감기를 갖는 변형된 폰 빌레브란트 인자 |
| WO2016142289A1 (en) * | 2015-03-06 | 2016-09-15 | Csl Behring Recombinant Facility Ag | Compounds for improving the half-life of von willebrand factor |
| EP4089109A3 (en) | 2015-05-22 | 2023-03-01 | CSL Behring Lengnau AG | Methods for preparing modified von willebrand factor |
| BR112017023785A2 (pt) | 2015-05-22 | 2018-07-17 | Csl Behring Recombinant Facility Ag | polipeptídeos do fator de von willebrand truncados para tratar hemofilia |
| US11077187B2 (en) | 2015-11-17 | 2021-08-03 | Oklahoma Medical Research Foundation | Epitope of optimized humanized monoclonal antibodies against activated protein C and uses thereof |
| RU2018128582A (ru) | 2016-01-07 | 2020-02-11 | Цсл Беринг Ленгнау Аг | Мутированный укороченный фактор фон виллебранда |
| DK3400238T3 (da) | 2016-01-07 | 2021-07-26 | CSL Behring Lengnau AG | Muteret von willebrand faktor |
| SG11201903954WA (en) | 2016-11-11 | 2019-05-30 | CSL Behring Lengnau AG | Truncated von willebrand factor polypeptides for extravascular administration in the treatment or prophylaxis of a blood coagulation disorder |
| US11814421B2 (en) | 2016-11-11 | 2023-11-14 | CSL Behring Lengnau AG | Truncated von Willebrand Factor polypeptides for treating hemophilia |
| CA3115535A1 (en) * | 2018-10-23 | 2020-04-30 | The Children's Hospital Of Philadelphia | Compositions and methods for modulating factor viii function |
| US11471497B1 (en) | 2019-03-13 | 2022-10-18 | David Gordon Bermudes | Copper chelation therapeutics |
| EP4069269A4 (en) * | 2019-12-06 | 2023-12-27 | The Children's Hospital Of Philadelphia | COMPOSITIONS AND METHODS FOR MODULATING FACTOR VIII FUNCTION |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5214033A (en) | 1983-03-31 | 1993-05-25 | Scripps Clinic & Research Foundation | Factor VIII coagulant polypeptides |
| US4757006A (en) | 1983-10-28 | 1988-07-12 | Genetics Institute, Inc. | Human factor VIII:C gene and recombinant methods for production |
| US5045455A (en) | 1984-01-12 | 1991-09-03 | Chiron Corporation | Factor VIII:C cDNA cloning and expression |
| SE8501050D0 (sv) | 1985-03-05 | 1985-03-05 | Kabivitrum Ab | Biologically active fragments of human antihemophilic factor and method for preparation thereof |
| JPH0788399B2 (ja) | 1985-04-12 | 1995-09-27 | ジェネティックス・インスチチュ−ト・インコ−ポレ−テッド | 新規プロコアギュラント蛋白質 |
| US5250421A (en) | 1986-01-03 | 1993-10-05 | Genetics Institute, Inc. | Method for producing factor VIII:C-type proteins |
| WO1987004187A1 (en) | 1986-01-03 | 1987-07-16 | Genetics Institute, Inc. | METHOD FOR PRODUCING FACTOR VIII:c-TYPE PROTEINS |
| AT388079B (de) | 1986-04-18 | 1989-04-25 | Helmut Ing Koenig | Backofen |
| US5422260A (en) * | 1986-05-29 | 1995-06-06 | Genetics Institute, Inc. -Legal Affairs | Human factor VIII:c muteins |
| US5451521A (en) * | 1986-05-29 | 1995-09-19 | Genetics Institute, Inc. | Procoagulant proteins |
| US4912040A (en) | 1986-11-14 | 1990-03-27 | Genetics Institute, Inc. | Eucaryotic expression system |
| CA1331157C (en) | 1987-04-06 | 1994-08-02 | Randal J. Kaufman | Method for producing factor viii:c-type proteins |
| DE3720246A1 (de) | 1987-06-19 | 1988-12-29 | Behringwerke Ag | Faktor viii:c-aehnliches molekuel mit koagulationsaktivitaet |
| US5004803A (en) | 1988-11-14 | 1991-04-02 | Genetics Institute, Inc. | Production of procoagulant proteins |
| NZ236094A (en) | 1989-11-17 | 1993-04-28 | Chiron Corp | Recombinant protein complex having human factor viii:c activity |
| US5661008A (en) | 1991-03-15 | 1997-08-26 | Kabi Pharmacia Ab | Recombinant human factor VIII derivatives |
| US5563045A (en) | 1992-11-13 | 1996-10-08 | Genetics Institute, Inc. | Chimeric procoagulant proteins |
| AU6486196A (en) | 1995-07-11 | 1997-02-10 | Chiron Corporation | Novel factor viii:c polypeptide analogs with altered protease sites |
| WO1997003194A1 (en) | 1995-07-11 | 1997-01-30 | Chiron Corporation | Lysine 1689 factor viii:c polypeptide analogs |
| EP0910628B1 (en) | 1996-04-24 | 2006-03-08 | The Regents of The University of Michigan | Inactivation resistant factor viii |
-
1997
- 1997-04-24 EP EP97927596A patent/EP0910628B1/en not_active Expired - Lifetime
- 1997-04-24 EP EP10157809A patent/EP2202242A1/en not_active Withdrawn
- 1997-04-24 PT PT06004484T patent/PT1754718E/pt unknown
- 1997-04-24 CA CA002252896A patent/CA2252896C/en not_active Expired - Fee Related
- 1997-04-24 DE DE69735421T patent/DE69735421T2/de not_active Expired - Lifetime
- 1997-04-24 DK DK06004484.9T patent/DK1754718T3/da active
- 1997-04-24 AT AT97927596T patent/ATE319817T1/de not_active IP Right Cessation
- 1997-04-24 WO PCT/US1997/006563 patent/WO1997040145A1/en not_active Ceased
- 1997-04-24 AU AU32027/97A patent/AU3202797A/en not_active Abandoned
- 1997-04-24 EP EP06004484A patent/EP1754718B1/en not_active Expired - Lifetime
- 1997-04-24 DE DE69740154T patent/DE69740154D1/de not_active Expired - Lifetime
- 1997-04-24 JP JP53821697A patent/JP3987114B2/ja not_active Expired - Fee Related
- 1997-04-24 AT AT06004484T patent/ATE502958T1/de active
-
2001
- 2001-04-11 US US09/819,098 patent/US6838437B2/en not_active Expired - Fee Related
-
2004
- 2004-10-26 US US10/974,534 patent/US7459534B2/en not_active Expired - Fee Related
-
2007
- 2007-04-09 JP JP2007101700A patent/JP4250661B2/ja not_active Expired - Fee Related